Notably, Provenge, a prostate cancer vaccine, exhibited promising outcomes using autologous DC pulsed with fusion antigen protein consisting of prostatic acid phosphatase (PAP) and GM--CSF, the first therapeutic cancer vaccine to be approved by the U.S. Food and Drug Administration in 2010, showed to prolong median OS by 4.1 months for metastatic castration resistant prostate cancer [12]. Here, ACP3 is linked to Familial prostate cancer.